Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy

American Journal of Transplantation

Volumn 6, Issue 6, 2006, Pages 1248-1256

  Mehra, M R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Calcineurin inhibitors; Cardiac allograft vasculopathy; Heart transplantation; Mycophenolate mofetil; Sirolimus

Indexed keywords

ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTIVIRUS AGENT; ASCORBIC ACID; AZATHIOPRINE; BIOLOGICAL MARKER; CALCINEURIN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; EVEROLIMUS; FOLIC ACID; GANCICLOVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ANGIOGRAPHY; ARTERY INTIMA PROLIFERATION; CARDIAC ALLOGRAFT VASCULOPATHY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIABETES CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DOPPLER FLOWMETRY; EARLY DIAGNOSIS; HEART MUSCLE REVASCULARIZATION; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR ULTRASOUND; LONG TERM CARE; PERCUTANEOUS CORONARY INTERVENTION; PLASMAPHERESIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REOPERATION; RESTENOSIS; SHORT SURVEY; STRESS ECHOCARDIOGRAPHY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION;

BIOLOGICAL MARKERS; CORONARY CIRCULATION; CORONARY DISEASE; HEART TRANSPLANTATION; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33745853542     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01314.x     Document Type: Short Survey

References (110)

1. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Keck BM, Hertz MI. The registry of the International Society for Heat and Lung Transplantation: Twenty-first official adult heart transplant report - 2004. J Heart Lung Transplant 2004; 23: 796-803.
2. Mehra MR, Ventura HO, Stapleton DD, Smart FW, Collins TC, Ramee SR. Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung Transplant 1995; 14: 632-639.
3. Moien-Afshari F, McManus BM, Laher I. Immunosuppression and transplant vascular disease: Benefits and adverse effects. Pharmacol Ther 2003; 100: 141-156.
4. Wong C, Ganz P, Miller L et al. Role of vascular remodeling in the pathogenesis of early transplant coronary artery disease: A multicenter prospective intravascular ultrasound study. J Heart Lung Transplant 2001; 20: 385-392.
5. Kobashigawa J, Wener L, Johnson J et al. Longitudinal study of vascular remodeling in coronary arteries after heart transplantation. J Heart Lung Transplant 2000; 19: 546-550.
6. Tsutsui H, Schoenhagen P, Ziada KM et al. Early constriction or expansion of the external elastic membrane area determines the late remodeling response and cumulative lumen loss in transplant vasculopathy: An intravascular ultrasound study with 4-year follow-up. J Heart Lung Transplant 2003; 22: 519-525.
7. Radio S, Wood S, Wilson J, Lin H, Winters G, McManus B. Allograft vascular disease: Comparison of heart and other grafted organs. Transplant Proc 1996; 28: 496-499.
8. Yamani MH, Tuzcu EM, Starling RC et al. Computerized scoring of histopathology for predicting coronary vasculopathy, validated by intravascular ultrasound. J Heart Lung Transplant 2002; 21: 850-859.
9. Mehra MR, Ventura HO, Chambers RB, Ramireddy K, Smart FW, Stapleton DD. The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: Time for a reappraisal. J Heart Lung Transplant 1997; 16: 743-751.
10. Brunner-La Rocca HP, Schneider J, Kunzli A, Turina M, Kiowski W. Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease. Transplantation 1998; 65: 538-543.
11. Mehra MR, Ventura HO, Chambers R et al. Predictive model to assess risk for cardiac allograft vasculopathy: An intravascular ultrasound study. J Am Coll Cardiol 1995; 26: 1537-1544.
12. Caforio AL, Tona F, Fortina AB et al. Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: Multivariate risk factor analysis and role of immunosuppression. Am J Transplant 2004; 4: 962-970.
13. Davis SF, Yeung AC, Meredith IT et al. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation 1996; 93: 457-462.
14. Fish RD, Nabel EG, Selwyn AP et al. Responses of coronary arteries of cardiac transplant patients to acetylcholine. J Clin Invest 1988; 81: 21-31.
15. Hollenberg SM, Klein LW, Parrillo JE et al. Changes in coronary endothelial function predict progression of allograft vasculopathy after heart transplantation. J Heart Lung Transplant 2004; 23: 265-271.
16. Libby P, Swanson SJ, Tanaka H. Immunopathology of coronary arteriosclerosis in transplanted hearts. J Heart Lung Transplant 1992; 11: 5-6.
17. Crisp SJ, Dunn MJ, Rose ML, Barbir M, Yacoub MA. Antiendothelial antibodies after heart transplantation: The accelerating factor in transplant-associated coronary artery disease. J Heart Lung Transplant 1994; 13: 1381-1392.
18. Wheeler CH, Collins A, Dunn MJ, Crisp SJ, Yacoub MH, Rose ML. Characterization of endothelial antigens associated with transplant-associated coronary artery disease. J Heart Lung Transplant 1995; 14: S188-S197.
19. Fredrich R, Toyoda M, Czer LS et al. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation 1999; 67: 385-391.
20. Rose ML. De novo production of antibodies after heart or lung transplantation should be regarded as an early warning system. J Heart Lung Transplant 2004; 23: 385-395.
21. Mills RM, Naftel DC, Kirklin JK et al. Heart transplant rejection with hemodynamic compromise: A multiinstitutional study of the role of endomyocardial cellular infiltrate. Cardiac Transplant Research Database. J Heart Lung Transplant 1997; 16: 813-821.
22. Bates RL, Frampton G, Rose ML, Murphy JJ. High diversity of non-human leukocyte antigens in transplant-associated coronary artery disease. Transplantation 2003; 75: 1347-1350.
23. Yamani MH, Erinc K, Starling RC et al. Donor intracranial bleeding is associated with advanced transplant coronary vasculopathy: Evidence from intravascular ultrasound. Transplant Proc 2004; 36: 2564-2566.
24. Mehra MR, Uber PA, Ventura HO, Scott RL, Park MH. The impact of mode of donor brain death on cardiac allograft vasculopathy: An intravascular ultrasound study. J Am Coll Cardiol 2004; 43: 806-810.
25. Pethig K, Heublein B, Meliss RR, Haverich A. Volumetric remodeling of the proximal left coronary artery: Early versus late after heart transplantation. J Am Coll Cardiol 1999; 34: 197-203.
26. Aranda JM, Pauly DF, Kerensky RA et al. Percutaneous coronary intervention versus medical therapy for coronary allograft vasculopathy. One center's experience. J Heart Lung Transplant 2002; 21: 860-866.
27. Sharpies LD, Jackson CH, Parameshwar J, Wallwork J, Large SR. Diagnostic accuracy of coronary angiography and risk factors for post-heart-transplant cardiac allograft vasculopathy. Transplantation 2003; 76: 679-682.
28. St Goar FG, Pinto FJ, Alderman EL et al. Intracoronary ultrasound in cardiac transplant recipients. In vivo evidence of "angiographically silent" intimal thickening. Circulation 1992; 85: 979-987.
29. Spes CH, Klauss V, Rieber J et al. Functional and morphological findings in heart transplant recipients with a normal coronary angiogram: An analysis by dobutamine stress echocardiography, intracoronary Doppler and intravascular ultrasound. J Heart Lung Transplant 1999; 18: 391-398.
30. Rickenbacher PR, Pinto FJ, Lewis NP et al. Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. Circulation 1995; 92: 3445-3452.
31. Kapadia SR, Nissen SE, Tuzcu EM. Impact of intravascular ultrasound in understanding transplant coronary artery disease. Curr Opin Cardiol 1999; 14: 140-150.
32. Kofoed KF, Czernin J, Johnson J et al. Effects of cardiac allograft vasculopathy on myocardial blood flow, vasodilatory capacity, and coronary vasomotion. Circulation 1997; 95: 600-606.
33. Mehra MR, Ventura HO, Uber PA, Scott RL, Park MH. Is all intimal proliferation created equal in cardiac allograft vasculopathy? The quantity-quality paradox. J Heart Lung Transplant 2003; 22: 118-123.
34. Kapadia SR, Nissen SE, Ziada KM et al. Development of transplantation vasculopathy and progression of donor-transmitted atherosclerosis: Comparison by serial intravascular ultrasound imaging. Circulation 1998; 98: 2672-2678.
35. Clausell N, Butany J, Molossi S et al. Abnormalities in intramyocardial arteries detected in cardiac transplant biopsy specimens and lack of correlation with abnormal intracoronary ultrasound or endothelial dysfunction in large epicardial coronary arteries. J Am Coll Cardiol 1995; 26: 110-119.
36. Yamani MH, Tuzcu EM, Starling RC et al. Computerized scoring of histopathology for predicting coronary vasculopathy, validated by intravascular ultrasound. J Heart Lung Transplant 2002; 21: 850-859.
37. Kobashigawa JA, Tobis JM, Starling RC et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: Outcomes after five years. J Am Coll Cardiol 2005; 45: 1532-1537.
38. Tuzcu EM, Kapadia SR, Sachar R et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 2005; 45: 1538-1542.
39. Weis M, Hartmann A, Olbrich HG, Hor G, Zeiher AM. Prognostic significance of coronary flow reserve on left ventricular ejection fraction in cardiac transplant recipients. Transplantation 1998; 65: 103-108.
40. Hollenberg SM, Klein LW, Parrillo JE et al. Changes in coronary endothelial function predict progression of allograft vasculopathy after heart transplantation. J Heart Lung Transplant 2004; 23: 265-271.
41. Potluri SP, Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO. Relationship among epicardial coronary disease, tissue myocardial perfusion, and survival in heart transplantation. J Heart Lung Transplant 2005; 24: 1019-1025.
42. Spes CH, Klauss V, Mudra H et al. Diagnostic and prognostic value of serial dobutamine stress echocardiography for noninvasive assessment of cardiac allograft vasculopathy: A comparison with coronary angiography and intravascular ultrasound. Circulation 1999; 100: 509-515.
43. Derumeaux G, Redonnet M, Soyer R, Cribier A, Letac B. Assessment of the progression of cardiac allograft vasculopathy by dobutamine stress echocardiography. J Heart Lung Transplant 1998; 17: 259-267.
44. Konig A, Spes CH, Schiele TM et al. Coronary Doppler measurements do not predict progression of cardiac allograft vasculopathy: Analysis by serial intracoronary Doppler, dobutamine stress echocardiography, and intracoronary ultrasound. J Heart Lung Transplant 2002; 21: 902-905.
45. Dandel M, Hummel M, Muller J et al. Reliability of tissue Doppler wall motion monitoring after heart transplantation for replacement of invasive routine screenings by optimally timed cardiac biopsies and catheterizations. Circulation 2001; 104:1184-191.
46. Knollmann FD, Bocksch W, Spiegelsberger S, Hetzer R, Felix R, Hummel M. Electron-beam computed tomography in the assessment of coronary artery disease after heart transplantation. Circulation 2000; 101: 2078-2082.
47. Ratliff NB, 3rd, Jorgensen CR, Gobel FL, Hodges M, Knickelbine T, Pritzker MR. Lack of usefulness of electron beam computed tomography for detecting coronary allograft vasculopathy. Am J Cardiol 2004; 94: 202-206.
48. Allen-Auerbach M, Schoder H, Johnson J et al. Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients. J Heart Lung Transplant 1999; 18: 211-219.
49. Evanochko WT, Buchthal SD, den Hollander JA et al. Cardiac transplant patients response to the (31)P MRS stress test. J Heart Lung Transplant 2002; 21: 522-529.
50. Muehling OM, Wilke NM, Panse P et al. Reduced myocardial perfusion reserve and transmural perfusion gradient in heart transplant arteriopathy assessed by magnetic resonance imaging. J Am Coll Cardiol 2003; 42: 1054-1060.
51. Mehra MR, Benza R, Deng MC, Russell S, Webber S. Surrogate markers for late cardiac allograft survival. Am J Transplant 2004; 4: 1184-1191.
52. Labarrere CA, Nelson DR, Cox CJ, Pitts D, Kirlin P, Halbrook H. Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation. JAMA 2000; 284: 457-464.
53. Pethig K, Heublein B, Kutschka I, Haverich A. Systemic inflammatory response in cardiac allograft vasculopathy: High-sensitive C-reactive protein is associated with progressive luminal obstruction. Circulation 2000; 102: III233-236.
54. Labarrere CA, Lee JB, Nelson DR, Al-Hassani M, Miller SJ, Pitts DE. C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: A prospective study. Lancet 2002; 360: 1462-1467.
55. Hognestad A, Endresen K, Wergeland R et al. Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. J Am Coll Cardiol 2003; 42: 477-482.
56. Eisenberg MS, Chen HJ, Warshofsky MK et al. Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation 2000; 102: 2100-2104.
57. Ventura HO, Mehra MR. C-Reactive protein and cardiac allograft vasculopathy. Is inflammation the critical link? J Am Coll Cardiol 2003; 42: 483-485.
58. Mehra MR, Uber PA, Potluri S, Ventura HO, Scott RL, Park MH. Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. Am J Cardiol 2004; 94: 454-458.
59. Tsutsui H, Ziada KM, Schoenhagen P et al. Lumen loss in transplant coronary artery disease is a biphasic process involving early intimal thickening and late constrictive remodeling: Results from a 5-year serial intravascular ultrasound study. Circulation 2001; 104: 653-657.
60. Qian Z, Hu W, Liu J, Sanfilippo F, Hruban RH, Baldwin WM, 3rd. Accelerated graft arteriosclerosis in cardiac transplants: Complement activation promotes progression of lesions from medium to large arteries. Transplantation 2001; 72: 900-906.
61. Azimzadeh AM, Pfeiffer S, Wu GS, Schroder C, Zhou H, Zorn GL 3rd, Kehry M, Miller GG, Rose ML, Pierson RN 3rd. Humoral immunity to vimentin is associated with cardiac allograft injury in nonhuman primates. Am J Transplant 2005; 10: 2349-2359.
62. Meier-Kriesche H-U, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291-1295.
63. Klauss V, Konig A, Spes C et al. Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy. Am J Cardiol 2000; 85: 266-269.
64. Meiser BM, Groetzner J, Kaczmarek I et al. Tacrolimus or cyclosporine: Which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation 2004; 78: 591-598.
65. Mehra MR, Uber PA, Scott RL, Park MH, Milani RV. Effect of immunosuppressive regimen on novel markers of atherothrombosis in heart transplantation: Homocysteine, c-reactive protein, and mean platelet volume. Transplant Proc 2002; 34: 1866-1868.
66. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
67. Allison AC, Kowalski WJ, Muller CJ, Waters RV, Eugui EM. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 1993; 25: S67-S70.
68. Richter MH, Zahn S, Kraus M, Mohr FW, Olbrich HG. Mycophenolate mofetil significantly reduces leukocyte graft infiltration after heterotopic cardiac transplantation in a rat model: Comparative study with cyclosporine and FK 506. J Heart Lung Transplant 2003; 22: 1107-1116.
69. Hosenpud JD, Bennett LE. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: An analysis of the Joint UNOS/ISHLT Thoracic Registry. Transplantation 2001; 72: 1662-1665.
70. Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66: 507-515.
71. Eisen HJ, Kobashigawa J, Keogh A et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005; 24: 517-525.
72. Kobashigawa J, Tobis J, Mentzer RM et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: Reanalysis of the Multicenter Trial. Am J Transplant 2006 (in press).
73. Rose ML, Smith J, Dureau G, Keogh A, Kobashigawa J. Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant 2002; 21: 282-285.
74. Weigel G, Griesmacher A, Karimi A, Zuckermann AO, Grimm M, Mueller MM. Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients. J Heart Lung Transplant 2002; 21: 1074-1079.
75. Moon JI, Kim YS, Kim MS et al. Effect of cyclosporine, mycophenolic acid, and rapamycin on the proliferation of rat aortic vascular smooth muscle cells: In vitro study. Transplant Proc 2000; 32: 2026-2027.
76. Mancini D, Pinney S, Burkhoff D et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48-53.
77. Keogh A, Richardson M, Ruygrok P et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. A randomized clinical trial. Circulation 2004; 110: 2694-2700.
78. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858.
79. Gupta A, Moustapha A, Jacobsen DW et al. High homocysteine, low folate, and low vitamin B6 concentrations: Prevalent risk factors for vascular disease in heart transplant recipients. Transplantation 1998; 65: 544-550.
80. Kutschka I, Pethig K, Harringer W, Haverich A, Struber M. Increased plasma homocysteine concentrations accelerate cardiac allograft vasculopathy. J Heart Lung Transplant 2004; 23: 1260-1265.
81. Nahlawi M, Seshadri N, Boparai N et al. Usefulness of plasma vitamin B(6), B(12), folate, homocysteine, and creatinine in predicting outcomes in heart transplant recipients. Am J Cardiol 2002; 89: 834-837.
82. Kutschka I, Pethig K, Struber M, Dieterich C, Harringer W, Haverich A. Homocysteine - a treatable risk factor for allograft vascular disease after heart transplantation? J Heart Lung Transplant 2001; 20: 743-746.
83. Cook RC, Parker S, Kingsbury K et al. Effective treatment of hyperhomocysteinemia in heart transplant recipients with and without renal failure. J Heart Lung Transplant 2001; 20: 310-315.
84. Aranda JM, Jr., Hill J. Cardiac transplant vasculopathy. Chest 2000; 118: 1792-1800.
85. Mehra MR, Raval NY. Metaanalysis of statins and survival in de novo cardiac transplantation. Transplant Proc 2004; 36: 1539-1541.
86. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-1402.
87. Fellstrom B. Cyclosporine nephrotoxicity. Transplant Proc 2004; 36: 220S-223S.
88. Mehra MR, Ventura HO, Smart FW, Collins TJ, Ramee SR, Stapleton DD. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am J Cardiol 1995; 75: 853-854.
89. Valantine HA, Gao SZ, Menon SG et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100: 61-66.
90. Petrakopoulou P, Kubrich M, Pehlivanli S et al. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation 2004; 110: II207-II212.
91. Haji SA, Starling RC, Avery RK et al. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant 2004; 23: 277-283.
92. Bonaros NE, Kocher A, Dunkler D et al. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. Transplantation 2004; 77: 890-897.
93. Vrtovec B, Thomas CD, Radovancevic R, Frazier OH, Radovancevic B. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients. J Heart Lung Transplant 2004; 23: 461-465.
94. Fang JC, Kinlay S, Beltrame J et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: A randomised trial. Lancet 2002; 359: 1108-1113.
95. Kinlay S, Behrendt D, Fang JC et al. Long-term effect of combined vitamins E and C on coronary and peripheral endothelial function. J Am Coll Cardiol 2004; 43: 629-634.
96. Marelli D, Laks H, Patel B et al. Heart transplantation in patients with diabetes mellitus in the current era. J Heart Lung Transplant 2003; 22: 1091-1097.
97. Valantine H, Rickenbacker P, Kemna M et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: A prospective study. Circulation 2001; 103: 2144-2152.
98. Mehra MR, Uber PA. TOR inhibitors and cardiac allograft vasculopathy: Is inhibition of intimal thickening an adequate surrogate of benefit? J Heart Lung Transplant 2003; 22: 501-504.
99. Taylor DO, Edwards LB, Mohacsi PJ et al. The registry of the International Society for Heart and Lung Transplantation: Twentieth official adult heart transplant report - 2003. J Heart Lung Transplant 2003; 22: 616-624.
100. Radovancevic B, McGiffin DC, Kobashigawa JA et al. Retransplantation in 7,290 primary transplant patients: A 10-year multiinstitutional study. J Heart Lung Transplant 2003; 22: 862-868.
101. Musci M, Loebe M, Wellnhofer E et al. Coronary angioplasty, bypass surgery, and retransplantation in cardiac transplant patients with graft coronary disease. Thorac Cardiovasc Surg 1998; 46: 268-274.
102. Benza RL, Zoghbi GJ, Tallaj J et al. Palliation of allograft vasculopathy with transluminal angioplasty: A decade of experience. J Am Coll Cardiol 2004; 43: 1973-1981.
103. Schnetzler B, Drobinski G, Dorent R et al. The role of percutaneous transluminal coronary angioplasty in heart transplant recipients. J Heart Lung Transplant 2000; 19: 557-565.
104. Jain SP, Ramee SR, White CJ et al. Coronary stenting in cardiac allograft vasculopathy. J Am Coll Cardiol 1998; 32: 1636-1640.
105. Halle AA, 3rd, DiSciascio G, Massin EK et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol 1995; 26: 120-128.
106. Parry A, Roberts M, Parameshwar J, Wallwork J, Schofield P, Large S. The management of post-cardiac transplantation coronary artery disease. Eur J Cardiothorac Surg 1996; 10: 528-532; discussion 553.
107. Frazier OH, Tuzun E, Eichstadt H et al. Transmyocardial laser revascularization as an adjunct to coronary artery bypass grafting: A randomized, multicenter study with 4-year follow-up. Tex Heart Inst J 2004; 31: 231-239.
108. Mehra MR, Uber PA, Prasad AK et al. Long-term outcome of cardiac allograft vasculopathy treated by transmyocardial laser revascularization: Early rewards, late losses. J Heart Lung Transplant 2000; 19: 801-804.
109. Thiery J, Meiser B, Wenke K, Engelschalk C, Reichart B, Seidel D. Heparin-induced extracorporeal low-density-lipoprotein plasmapheresis (HELP) and its use in heart transplant patients with severe hypercholesterolemia. Transplant Proc 1995; 27: 1950-1953.
110. Park JW, Merz M, Braun P. Regression of transplant coronary artery disease during chronic low-density lipoprotein-apheresis. J Heart Lung Transplant 1997; 16: 290-297.